Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BVA-200 vs BVA-100 Validation Study

NCT06227819 is registered in ClinicalTrials.gov with Daxor Corporation as lead sponsor.

NCT NCT06227819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06227819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BVA-200 vs BVA-100 Validation Study
Lead sponsor
Daxor Corporation
Phase
Observational
Overall status
Completed
Start date
May 23, 2023
Completion date
November 30, 2023
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, clotting disorder, diabetes, heart failure, high blood pressure, high cholesterol, kidney diseases, other disease, thyroid diseases, trauma